98%
921
2 minutes
20
This study explores the potential of H-NMR spectroscopy-based metabolic profiling in various biofluids as a diagnostic and predictive modality to assess disease severity in individuals with 5q spinal muscular atrophy. A total of 213 biosamples (urine, plasma, and CSF) from 153 treatment-naïve patients with SMA across five German centers were analyzed using H-NMR spectroscopy. Prediction models were developed using machine learning algorithms which enabled the patients with SMA to be grouped according to disease severity. A quantitative enrichment analysis was employed to identify metabolic pathways associated with disease progression. The results demonstrate high sensitivity (84-91%) and specificity (91-94%) in distinguishing treatment-naïve patients with SMA from controls across all biofluids. The urinary and plasma profiles differentiated between early-onset (type I) and later-onset (type II/III) SMA with over 80% accuracy. Key metabolic differences involved alterations in energy and amino acid metabolism. This study suggests that H-NMR spectroscopy based metabolic profiling may be a promising, non-invasive tool to identify patients with SMA and for severity stratification, potentially complementing current diagnostic and prognostic strategies in SMA management.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11594255 | PMC |
http://dx.doi.org/10.3390/ijms252212123 | DOI Listing |
Int J Surg Pathol
September 2025
Department of Pathology, The Thirteenth People's Hospital of Chongqing, Chongqing, China.
Soft tissue sarcomas are a heterogeneous group of malignancies arising from mesenchymal cells. Recent advancements in genomic profiling have identified novel gene fusions in these tumors, offering new insights into their pathogenesis and potential therapeutic targets. Here, we describe a spindle cell sarcoma harboring a novel gene fusion.
View Article and Find Full Text PDFJ Clin Invest
September 2025
Department of Genetics, Research Institute of Environmental Medicine, Nagoya University, Nagoya, Japan.
Few drugs are available for rare diseases due to economic disincentives. However, tailored medications for extremely-rare disorders (N-of-1) offer a ray of hope. Artificial antisense oligonucleotides (ASOs) are now best known for their use in spinal muscular atrophy (SMA).
View Article and Find Full Text PDFJCI Insight
September 2025
Edinburgh Medical School: Biomedical Sciences & Euan MacDonald Centre for M, University of Edinburgh, Edinburgh, United Kingdom.
Spinal muscular atrophy (SMA) is a neuromuscular disease caused by low levels of SMN protein. Several therapeutic approaches boosting SMN are approved for human patients, delivering remarkable improvements in lifespan and symptoms. However, emerging phenotypes, including neurodevelopmental comorbidities, are being reported in some treated SMA patients, indicative of alterations in brain development.
View Article and Find Full Text PDFCureus
September 2025
General Surgery, Tufts University School of Medicine, Boston, USA.
Superior mesenteric artery (SMA) syndrome is a rare condition characterized by the narrowing of the space between the SMA and the aorta, resulting in the compression of the third portion of the duodenum. This syndrome has many names, including cast syndrome, arterio-mesenteric duodenal compression syndrome, and Wilkie syndrome. This is attributed to the loss of the intervening mesenteric fat pad, posing diagnostic and therapeutic challenges due to its nonspecific presentation.
View Article and Find Full Text PDFCureus
August 2025
Department of Internal Medicine, Local Health Unit of Santa Maria, Lisbon, PRT.
Polyarteritis nodosa (PAN) rarely affects both intracranial and mesenteric arteries. Evidence on optimal timing of revascularisation and the role of interleukin-6 blockade remains limited. A 73-year-old man with longstanding ankylosing spondylitis presented with weight loss and elevated inflammatory markers.
View Article and Find Full Text PDF